Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hormone whodunit: clues for solving the case of intratumor androgen production.

Literature DB >> 25135482

Hormone whodunit: clues for solving the case of intratumor androgen production.

Abstract

One of the key mechanisms by which prostate cancer cells evade hormone therapy is through intratumor testosterone production. New evidence points toward androstenedione as a potential precursor of intratumor androgen production and furthers nomination of AKR1C3 as a therapeutic target in advanced disease. ©2014 American Association for Cancer Research.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Androgens
Androstenedione

Year: 2014 PMID： 25135482 PMCID： PMC4216738 DOI： 10.1158/1078-0432.CCR-14-1188

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

12 in total

1. Abiraterone in metastatic prostate cancer.

Authors: Charles J Ryan; Arturo Molina; Thomas Griffin
Journal: N Engl J Med Date: 2013-04-11 Impact factor: 91.245

Review 2. AKR1C3 as a target in castrate resistant prostate cancer.

Authors: Adegoke O Adeniji; Mo Chen; Trevor M Penning
Journal: J Steroid Biochem Mol Biol Date: 2013-06-06 Impact factor: 4.292

Review 3. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

Authors: Karen E Knudsen; Trevor M Penning
Journal: Trends Endocrinol Metab Date: 2010-02-06 Impact factor: 12.015

4. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors: Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701

Review 5. Molecular pathology and prostate cancer therapeutics: from biology to bedside.

Authors: Daniel Nava Rodrigues; Lisa M Butler; David Lorente Estelles; Johann S de Bono
Journal: J Pathol Date: 2014-01 Impact factor: 7.996

6. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors: Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal: Cancer Res Date: 2006-03-01 Impact factor: 12.701

7. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701

8. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Authors: Elahe A Mostaghel; Stephanie T Page; Daniel W Lin; Ladan Fazli; Ilsa M Coleman; Lawrence D True; Beatrice Knudsen; David L Hess; Colleen C Nelson; Alvin M Matsumoto; William J Bremner; Martin E Gleave; Peter S Nelson
Journal: Cancer Res Date: 2007-05-15 Impact factor: 12.701

Hormone whodunit: clues for solving the case of intratumor androgen production.

1. Abiraterone in metastatic prostate cancer.

Review 2. AKR1C3 as a target in castrate resistant prostate cancer.

Review 3. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.

4. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Review 5. Molecular pathology and prostate cancer therapeutics: from biology to bedside.

6. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

7. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

8. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

Review 9. Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences.

Review 10. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Review 1. Androgen Signaling in Prostate Cancer.

Review 2. Molecular Mechanism of Tanshinone against Prostate Cancer.